[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362163-105":59,"doc-detail-362163-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","synthetic-essentiality-of-isoprenylcysteine-carboxylmethyltransferase-in-pten-deficient-triple-negative-breast-cancer","Synthetic essentiality of isoprenylcysteine carboxylmethyltransferase in PTEN deficient triple negative breast cancer","","PTEN deficiency is frequently seen across cancers, including triple-negative breast cancer, yet PTEN loss-of-function mutations are not directly targetable by drugs. A synthetic lethality strategy using combinatorial CRISPR screening identified ICMT loss as selectively lethal in PTEN-deficient tumors. ICMT inhibition, genetic or pharmacologic, reverses PTEN-loss–driven transformation and reduces epithelial-mesenchymal transition and cancer stem cell populations. Mechanistically, ICMT loss disrupts the PIP3–GEF–Rac1–PI3K positive feedback loop by enhancing Rac1–RhoGDI association, suppressing Rac1 activity and stability, promoting aggregated protein accumulation, activating UPR signaling, and triggering cell death.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/synthetic-essentiality-of-isoprenylcysteine-carboxylmethyltransferase-in-pten-deficient-triple-negative-breast-cancer/362163/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/synthetic-essentiality-of-isoprenylcysteine-carboxylmethyltransferase-in-pten-deficient-triple-negative-breast-cancer/362163.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is a synthetic lethality approach needed for PTEN-deficient tumors?","Question",{"text":112,"@type":113},"PTEN loss-of-function mutations are not directly druggable, limiting conventional targeted options. Synthetic lethality offers a way to find vulnerabilities specifically lethal in the PTEN-deficient context.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the CRISPR screening identify as a synthetic lethal partner of PTEN deficiency?",{"text":117,"@type":113},"The study identified ICMT (isoprenylcysteine carboxylmethyltransferase) loss as synthetic lethal with PTEN deficiency through combinatorial CRISPR screening.",{"name":119,"@type":110,"acceptedAnswer":120},"How does ICMT loss lead to reduced cancer aggressiveness and cell death?",{"text":121,"@type":113},"ICMT loss disrupts the PIP3–GEF–Rac1–PI3K positive feedback loop by increasing physical association of Rac1 with RhoGDI, inhibiting Rac1 activity and stability. It also promotes accumulated aggregated proteins that activate UPR signaling, ultimately resulting in cell death.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362163,1790194609,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Park etal. Experimental Hematology & Oncology (2026) 15:4 [https://doi.org/10.1186/s40164-025-00738-0](https://doi.org/10.1186/s40164-025-00738-0)  \nExperimental Hematology & Oncology  \nCORRESPONDENCE Open Access  \nSynthetic essentiality of isoprenylcysteine carboxylmethyltransferase in PTEN deficient triple negative breast cancer  \nByung-Sun Park 1, Jaeyeol Kim1,2, Dong-Chan Seo3, Ga-Eun Choi 1, Jin-Ju Seo4, Seung Eun Lee3* and Tackhoon Kim 1,2,5*  \nAbstract  \nPTEN deficiency is frequently observed in various cancers, including triple-negative breast cancer. However,  \nPTEN loss-of-function mutations are not directly druggable, necessitating a synthetic lethality approach for treating PTEN-deficient tumors. Utilizing combinatorial CRISPR screening, we identified ICMT (isoprenylcysteine carboxylmethyltransferase) loss as synthetic lethal with PTEN deficiency. Genetic or pharmacological inhibition of ICMT effectively reversed cellular transformation induced by PTEN loss. Mechanistically, ICMT loss disrupts the positive feedback loop involving PIP3-PIP3-dependent guanine nucleotide exchange factor (GEF)-Rac1-PI3K by increased physical association of Rac1 and RhoGDI, inhibiting Rac1 activity and stability. Disruption of this feedback loop attenuates epithelial-mesenchymal transition and reduces the cancer stem cell population. Additionally, ICMT loss leads to the accumulation of aggregated proteins, which activates the unfolded protein response (UPR) signaling, ultimately resulting in cell death. Cysmethynil, an ICMT inhibitor, effectively suppresses PTEN-mutant cancer growth in xenograft models. Collectively, our study establishes ICMT as a promising therapeutic target for treating PTEN-mutant cancers.  \n*Correspondence: Seung Eun Lee[selee@kist. re.kr](selee@kist. re.kr)[ ](selee@kist. re.kr)Tackhoon Kim [tackhoon@kist. re.kr](tackhoon@kist. re.kr)  \n1Medicinal Materials Research Center, Korea Institute of Science and Technology, 5 Hwarangro14gil, SeongbukGu, Seoul  \n02792, Republic of Korea  \n2Department of Life Sciences, Korea University, 145 AnamRo, SeongbukGu, Seoul 02841, Republic of Korea  \n3Research Animal Resources Center, Korea Institute of Science and Technology, 5 Hwarangro14gil, SeongbukGu, Seoul  \n02792, Republic of Korea  \n4Technological Convergence Center, Korea Institute of Science and Technology, 5 Hwarangro14gil, SeongbukGu, Seoul  \n02792, Republic of Korea  \n5Division of Bio-Medical Science and Technology, Korea National University of Science and Technology, 217 GajeongRo YuseongGu, Daejeon 34113, Republic of Korea  \nTo the editor,  \nPTEN loss-of-function is frequently observed in cancers such as triple-negative breast cancer (TNBC). However, PTEN mutations are not directly druggable, and alternative therapeutic approaches, including PI3K inhibitors and statins, have shown limited success due to toxicity or insufficient efficacy against PTEN-deficient tumors [1]. These limitations prompted the exploration of synthetic lethality as a therapeutic strategy for targeting PTEN-deficient tumors.  \nTo this end, we conducted CRISPR-Cas9 screens using isogenic MCF10A cells (PTEN wild-type and knockout). We utilized a pairwise combinatorial sgRNA library with one sgRNA targeting PTEN and another targeting 2,305 druggable genes [2], enabling simultaneous modeling of PTEN deficiency and screening (Fig. 1A, Fig S1A–D). While most genes equally influenced cell  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other thi","cbCaioH2YJWIU2bx","https://ap.wps.com/l/cbCaioH2YJWIU2bx","pdf",4540635,"English","# Abstract\n## CRISPR screening and synthetic lethal identification\n## ICMT inhibition and reversal of PTEN-loss effects\n## Mechanism: Rac1-RhoGDI feedback disruption and UPR-mediated death\n## Therapeutic potential in xenograft models","[{\"question\":\"Why is a synthetic lethality approach needed for PTEN-deficient tumors?\",\"answer\":\"PTEN loss-of-function mutations are not directly druggable, limiting conventional targeted options. Synthetic lethality offers a way to find vulnerabilities specifically lethal in the PTEN-deficient context.\"},{\"question\":\"What did the CRISPR screening identify as a synthetic lethal partner of PTEN deficiency?\",\"answer\":\"The study identified ICMT (isoprenylcysteine carboxylmethyltransferase) loss as synthetic lethal with PTEN deficiency through combinatorial CRISPR screening.\"},{\"question\":\"How does ICMT loss lead to reduced cancer aggressiveness and cell death?\",\"answer\":\"ICMT loss disrupts the PIP3–GEF–Rac1–PI3K positive feedback loop by increasing physical association of Rac1 with RhoGDI, inhibiting Rac1 activity and stability. It also promotes accumulated aggregated proteins that activate UPR signaling, ultimately resulting in cell death.\"}]","Synthetic essentiality of isoprenylcysteine carboxylmethyltransferase in PTEN deficient triple negative breast cancer | PDF",1790146624,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb0668a3a5cacab84b0494e6364aa202.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1561841bf64b4ae61c2bd618715ff681.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68a1232fe568506f547b35b75baaa5e5.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b260355bfcd4998c96a2558eaae86890.webp",980,1306]